More news about evitria

Biotech service provider evitria backed by two new investors

21.12.2018 08:20

Related tags

Antibody

AFINUM, SHS and the management invest in evitria, a leading provider of custom antibodies. Investors and management plan to further push internationalization in the years to come, supported by an active customer acquisition program.

Evitria, based in Schlieren, supplies large pharmaceutical and biotech companies with customized antibodies for research purposes. The company was founded 2010 by Markus Hildinger. Customers of evitria are typically renowned pharmaceutical and biotech companies as well as research institutions. Many of them are leading producers of blockbuster antibody drugs. The customers have a constant demand for specific antibodies tailored to their respective research purposes; they use evitria as a highly specialized and trustworthy outsourcing partner.

Through the deployment of a unique, highly standardized and automized production process, evitria is able to minimize throughput times and guarantees high concentration and quality levels. The company has been conducting more than 30,000 transfections and has been producing more than 5,000 different antibodies.

AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG, advised by AFINUM Management GmbH, acts as lead investor und majority owner and has jointly invested with SHS V Medtech Investments GmbH & Co. KG and management into evitria. The aim of the investors is to develop new customer groups and establish a business unit in the USA to serve the local market directly. This is the first joint investment for SHS and AFINUM.

(Press release / SK)
Picture: Kateryna Kon / Fotolia

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Related tags

Read more about

More news about evitria
Please login or
register to use the
bookmark feature

Related tags

Read more about

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

 

Principal

18.01.2019
Editorial

Good times for pioneers

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS